A new combination immunotherapy approach with anti-PD-L1 and HER2/neu loaded dendritic cell vaccine along with saponin adjuvant

被引：0
|
作者：
Ozverel, C. S. [1 ]
Karaboz, I. [1 ]
Nalbantsoy, A. [2 ]
机构：
[1] Ege Univ, Dept Biol, Fac Sci, Izmir, Turkey
[2] Ege Univ, Bioengn Dept, Fac Engn, Izmir, Turkey
来源：
EUROPEAN JOURNAL OF CANCER | 2018年 / 92卷
关键词：
D O I：
10.1016/j.ejca.2018.01.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P01.05
引用
收藏
页码：S6 / S7
页数：5
相关论文
共 31 条
  • [31] Trial in progress: A phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer.
    LoRusso, Patricia
    Pilat, Mary Josephine Paula
    Santa-Maria, Cesar Augusto
    Connolly, Roisin M.
    Roesch, Erin Elizabeth
    Afghahi, Anosheh
    Han, Hyo S.
    Nanda, Rita
    Wulf, Gerburg M.
    Assad, Hadeel
    Park, Haeseong
    Dees, Elizabeth Claire
    Force, Jeremy Meyer
    Noonan, Anne M.
    Brufsky, Adam
    Abramson, Vandana G.
    Haley, Barbara B.
    Buys, Saundra S.
    Sharon, Elad
    Schalper, Kurt A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
1234